Two cases of mycosis fungoides treated by reduced‐intensity cord blood transplantation

Tsuji, Hitomi; Wada, Takashi; Murakami, Masamoto; Kashiwagi, Takayuki; Ito, Yasuhiro; Ishida‐Yamamoto, Akemi; Jimbo, Junko; Shindo, Motohiro; Sato, Kazuya; Kohgo, Yutaka; Iizuka, Hajime

doi:10.1111/j.1346-8138.2010.00985.x

Cited by 11 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone marrow graft is a more invasive method for the donor as it requires bone marrow aspiration under general anesthesia. Data with cord blood transplantation in CTCL are limited but have been mostly reported in Japanese cases [ 15 , 42 , 44 , 45 ].…”

Section: Different Conditioning Approaches and Types Of Donorsmentioning

confidence: 99%

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Dumont

Latour

Ram‐Wolff

et al. 2020

Cancers

View full text Add to dashboard Cite

Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that develop primarily in the skin. They account for almost 80% of primary cutaneous lymphomas. Epidermotropic CTCLs (mycosis fungoides (MF) and Sézary syndrome (SS)) are the most common form of CTCL. The course of the disease ranges from an indolent clinical behavior in early-stage disease to an aggressive evolution in the advanced stages. Advanced-stage disease is defined by the presence of tumors, erythroderma, or significant blood, nodal or visceral involvement. Advanced-stage disease is characterized by frequent disease relapses, refractory disease, a severely impaired quality of life and reduced overall survival. In the last twenty-five years, allogeneic hematopoietic stem cell transplantation (HSCT) has led to prolonged remissions in advanced CTCL, presumably linked to a graft-versus-lymphoma effect and is thus emerging as a potential cure of the disease. However, the high post-transplant relapse rate and severe morbidity and mortality associated with graft-versus-host disease and infections are important issues. Allogeneic HSCT is thus mostly considered in young patients with no comorbidities and an aggressive, advanced-stage CTCL. Allogeneic HSCT gives the best results in patients with a pre-transplant complete remission of the lymphoma. For this reason, one of the challenges is to define the best time to consider allogeneic HSCT in the disease course. Early identification of patients at high risk for progression is important to identify candidates who may benefit from allogeneic HSCT before their disease becomes treatment-refractory. This review describes the role of allogeneic HSCT in CTCL, summarizes the published data and future perspectives in this area.

show abstract

Section: Different Conditioning Approaches and Types Of Donorsmentioning

confidence: 99%

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Dumont

Latour

Ram‐Wolff

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Causes of mortality included sepsis, metastatic nonsmall cell lung cancer, and disease progression 156. Cord blood transplantation has also been attempted with some success in Japan in cases of failure or inability to attempt allogeneic HSCT 157,158…”

Section: Current and Emerging Therapies For Advanced-stage Diseasementioning

confidence: 99%

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options

Horwitz²,

Moskowitz³

et al. 2012

CMAR

View full text Add to dashboard Cite

Cutaneous T cell lymphomas (CTCL) clinically and biologically represent a heterogeneous group of non-Hodgkin lymphomas, with mycosis fungoides and Sézary syndrome being the most common subtypes. Over the last decade, new immunological and molecular pathways have been identified that not only influence CTCL phenotype and growth, but also provide targets for therapies and prognostication. This review will focus on recent advances in the development of therapeutic agents, including bortezomib, the histone deacetylase inhibitors (vorinostat and romidepsin), and pralatrexate in CTCL.

show abstract

“…Moreover, recipients from matched related donors have a better outcome than those from matched unrelated donors . These studies are mainly done in Western countries and there are very few studies on HSCT for MF/SS in Japan . Studies regarding HSCT for CTCL other than MF/SS are limited all over the world.…”

Section: Introductionmentioning

confidence: 99%

Hematopoietic stem cell transplantation for cutaneous T‐cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil

Oka

Sugaya

Cury‐Martins

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

Some patients with cutaneous T-cell lymphoma (CTCL) show a miserable clinical course and the only option that can induce long-term remission for advanced CTCL may be hematopoietic stem cell transplantation (HSCT). So far, studies on HSCT for CTCL patients have been limited. In this study, we summarized 11 cases with CTCL treated with HSCT, including nine cases in Japan and two cases in Brazil. The patients were five cases with mycosis fungoides (MF), two cases with Sézary syndrome (SS), three cases with anaplastic large cell lymphoma, and one case with primary cutaneous peripheral T-cell lymphoma, not otherwise specified (PTL-NOS). Currently, seven out of 11 cases are alive (at 13-108 months after transplantation) and four died at 15 days to 14 months after transplantation. When focusing on the eight patients who received allogeneic HSCT for MF/SS and PTL-NOS, all four patients at 45 years old or under are alive at present. One case showed relapse in the skin. On the other hand, one out of the other four patients at over 45 years old survived. Engraftment failure was seen in one case and all the other three cases experienced relapse. Although this is only a case series with a small number, our study has suggested that we should be careful about age when treating patients with MF/SS by allogeneic HSCT.

show abstract

Two cases of mycosis fungoides treated by reduced‐intensity cord blood transplantation

Cited by 11 publications

References 43 publications

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options

Hematopoietic stem cell transplantation for cutaneous T‐cell lymphoma: Summary of 11 cases from two facilities in Japan and Brazil

Contact Info

Product

Resources

About